Pharminent

Novo gets US backing for Victoza cardiovascular data

US regulatory advisors are backing the claim that Novo Nordisks’ Victoza reduces cardiovascular risk in patients with diabetes. http://www.pharmatimes.com/news/novo_gets_us_backing_for_victoza_cardiovascular_data_1196325

Filed under: Diabetes, GLP-1